Season 2, Episode 4 — The Word That Covered the Spread

A hospital system in Indianapolis paid the federal government $345 million last year to settle systematic kickback allegations. The day after the settlement, that hospital continued to buy pharmaceuticals at 25 to 50 percent below wholesale through a federal program called 340B. It continued to bill Medicare, Medicaid, and private insurance at the full retail price for those same drugs. No federal agency reviewed its eligibility. No mechanism exists in the architecture that would prompt that review.

The hospital paid the fine. The hospital kept the discount.

This week on Edge of the Story, we go to where the most expensive version of the season's question lives. The pharmaceutical reimbursement program known as 340B. A program designed in 1992 to help safety-net hospitals afford drugs for low-income patients. Today, one of the largest government drug programs in the country — with no public mechanism to verify whether the discounted drugs ever reach the patients the program was designed to serve. The American Hospital Association went to federal court in December 2025 and successfully blocked a transparency pilot that would have begun to answer that question. The word the hospital lobby used to block the transparency requirement was patient care.

Meanwhile, the President's Most Favored Nation executive order has reached agreements with all 17 major pharmaceutical manufacturers. TrumpRx.gov now offers 750 drugs to consumers. Twelve million unique visitors. $500 million in estimated savings. The word on that program is transparency.

Four words now fight over the same pile of money — safety net, national security, patient care, transparency. Four institutions deploying them. And not one of the words describes the patient at the pharmacy counter trying to afford the prescription her doctor just wrote.

The Company Moment is the strongest positive story of the season. A radiologist with a math degree from Oxford sent a cold email to twenty-seven billionaires. One of them — Mark Cuban — wrote back. They built a pharmacy that publishes its prices. A generic cancer drug that costs over $9,000 per month through traditional pharmacy channels sells on their site for $14.40. The architecture is not broken. The architecture is a choice. And someone chose to build a different one.

SHOW NOTES — S2E4

 THE 340B PROGRAM — PUBLIC RESOURCES

340B OPAIS — Public Database to Search 340B Hospitals

https://340bopais.hrsa.gov

HRSA Office of Pharmacy Affairs

https://www.hrsa.gov/opa

Community Health Network $345M settlement — DOJ

https://www.justice.gov/usao-sdin/pr/community-health-network-pay-345-million-resolve-false-claims-act-allegations

THE 340B TRANSPARENCY LAWSUIT

American Hospital Association v. HHS — court filings

https://www.aha.org/press-releases

HRSA proposed 340B pilot transparency program

https://www.hrsa.gov/opa/program-requirements

THE MOST FAVORED NATION EXECUTIVE ORDER

Executive Order on MFN Prescription Drug Pricing, May 12, 2025

https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/

Pharmaceutical Tariff Executive Order, April 2, 2026

https://www.whitehouse.gov/presidential-actions/2026/04/pharmaceutical-tariffs/

Pharmacy Times — Roundup of All 16 MFN Agreements

https://www.pharmacytimes.com/view/round-up-every-most-favored-nation-agreement-with-the-trump-administration

Regeneron MFN agreement — April 28, 2026 White House fact sheet

https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-announces-deal-with-regeneron-to-bring-most-favored-nation-pricing-to-american-patients/

TRUMPRX

TrumpRx.gov — Federal Direct-to-Consumer Pharmacy Site

https://www.trumprx.gov

Oz announces 160 more drugs added to TrumpRx — Breitbart, June 2, 2026

https://www.breitbart.com/politics/2026/06/02/oz-announces-160-more-drugs-being-added-to-trumprx/

THE COST PLUS DRUGS COMPANY MOMENT

The Mark Cuban Cost Plus Drug Company

https://www.costplusdrugs.com

How Cost Plus Drugs Sets Its Prices — Company Disclosure

https://costplusdrugs.com/how-its-priced/

Dr. Alex Oshmyansky founder profile

https://www.statnews.com/2023/02/14/cost-plus-drug-company-cuban-oshmyansky/

Imatinib comparison — Cost Plus Drugs versus retail pharmacy pricing

https://costplusdrugs.com/medications/imatinib-mesylate-400mg-tablet/

FOR FURTHER READING

340B Program History — Congressional Research Service

https://crsreports.congress.gov/product/pdf/R/R45709

MFN Drug Pricing Executive Order Legal Analysis — Library of Congress

https://www.congress.gov/crs-product/LSB11319

46brooklyn drug pricing research — nonprofit drug pricing analysis

https://www.46brooklyn.com

Have you ever been in a room where something shifted—but no one said it out loud?

Share your story at www.edgeofthestory.com/heard
.
If we feature it, we’ll send you an Edge of the Story notebook—because some observations are worth writing down.

Transcript

The $345M Settlement Contradiction

SPEAKER_00 0:05

A hospital system in Indianapolis paid the federal government $345 million last year. The settlement was for systematic kickbacks. The hospital had been paying recruited specialists above market compensation to capture their downstream Medicare referrals, then awarding bonuses tied to referral volume. The Department of Justice called it a False Claims Act violation. The settlement was one of the largest health care fraud settlements in Indiana history. The day after the settlement, that hospital continued to buy pharmaceuticals at 25 to 50 percent below wholesale. Through a federal program called 340B, it continued to bill Medicare, Medicaid, and private insurance at the full retail price for those same drugs. The spread between the discount and the retail price is what 340B hospitals call their margin. The federal government calls it a benefit for safety net hospitals serving low-income patients. No federal agency reviewed the hospital's 340B eligibility after the fraud settlement. No mechanism exists in the architecture that would have prompted that review. The hospital paid the fine. The hospital kept the discount. Whether you're in your car, out on a run, somewhere in the middle of your day, or in the shop bending wire, there are moments that don't announce themselves. They don't raise their voice, they don't stop the room, but they change everything. This is Edge of the Story, Season 2, Episode 4. I'm Daryl Best. Last week we asked who actually goes to prison when the press conferences happen and who never does. This week we go to where the most expensive version of that question lives. The pharmaceutical reimbursement program known as 340B, a program designed in 1992 to help safety net hospitals afford drugs for low income patients, today one of the largest government drug programs in the country. And we ask a question the program's defenders do not want asked. When the hospital paid $345 million in settlements and kept its discount the next day, what word covered the arrangement that allowed that to happen? We're not investigating the headline. We're investigating how the headline got in the room. Last week we documented what ground level fraud looks like. A daycare owner submitting thirteen thousand false claims while under federal indictment, a cosmetic doctor billing Medicare for migraine treatments while on vacation in Cabo, two hundred and eighty eight shell companies behind doors with no doorknobs in Columbus, Ohio. Those cases involve hundreds of millions of dollars, sometimes billions. They are real. The press conferences are real. The arrests are real. This week we go where the dollars are larger, where the operators are not shell companies but hospital systems and pharmaceutical manufacturers with quarterly earnings calls, where the word covering the arrangement is not medically necessary or end of life care. This week the words are safety net, national security, patient care, transparency, four different words, four different institutions, the same pile of money. And not one of them describes the patient.

Three Headlines About One System

SPEAKER_00 3:50

Julia, what headlines do you have for us this week?

SPEAKER_01 3:54

Well, Darrell, we have three headlines. Our first headline comes from the Department of Justice, USC Attorney's Office in the Southern District of Indiana, in December of 2024. The headline reads: Community Health Network in Indianapolis pays $345 million to settle kickback allegations, continues receiving 340B discounts. Community Health Network paid $345 million to settle False Claims Act allegations that it systematically overpaid recruited specialists to capture their downstream Medicare referrals, then awarded bonuses tied to that referral volume. The settlement was among the largest healthcare fraud settlements in Indiana history. Community Health Network was a 340 B covered entity at the time of the alleged misconduct. It remained a 340 B covered entity after the settlement. The federal program that provides hospitals with discounted drug pricing has no mechanism to review eligibility based on fraud settlements. The hospital paid the fine. The hospital kept the discount. Our second headline comes from the American Hospital Association VHHS case and its federal court filings in December 2025. Its headline reads Hospital lobby sues to block 340B transparency pilot program, Federal Judge Grant's injunction. The American Hospital Association and other hospital industry groups sued the Department of Health and Human Services to block a pilot program that would have required certain hospitals to submit data on how their 340B discounted drugs were actually used. A federal judge granted an injunction blocking the requirement in December 2025. The hospital's legal argument relied on administrative procedure grounds. The word they used in public statements to defend the position was patient care. They argued that requiring data submission would burden hospitals and harm patients. The word patient care was used to prevent the government from finding out whether the program served patients. Our last headline comes from a White House press briefing by CMS administrator Dr. Mehmet Oz on June 2nd, 2026. That headline announces Oz announces 160 more drugs added to Trump RX. 750 drugs total cause million visitors, 500 million in estimated savings. CMS administrator Dr. Mehmet Oz announced at the June 2nd White House press briefing that TrumRX.gov now offers 750 drugs at prices the president's most favored nation initiative negotiated with manufacturers. The site has received approximately 12 million unique visitors since launch in February. Oz cited estimated savings of $500 million and rising. Medicare beneficiaries will be able to obtain GLP1 weight loss drugs at $50 per month starting July 1st. The word OS used was transparency. It's a transparency site, he said. It gives everybody the ability to make important decisions about medications they're purchasing with full knowledge of what the cost of those medications are. Two transparencies. The hospital lobby in federal court blocking one, the federal government launching another, the same word pointing in opposite directions. Three headlines. All sources are in our show notes.

How 340B Discounts Create A Margin

SPEAKER_01 7:33

In 1992, Congress created the 340B drug pricing program. The premise was straightforward. Pharmaceutical manufacturers participating in Medicaid had to sell their outpatient drugs at steep discounts, 25 to 50% below wholesale, to a defined set of hospitals and clinics. The hospitals were supposed to be safety net providers, institutions serving a disproportionate share of low-income patients, places where the discount would translate into care for people who could not otherwise afford it. The word on the legislation was safety net. Nobody argued against it in 1992. Nobody argues against safety net hospitals serving low-income patients today. The word pre-wins the argument before the argument begins. The Health Resources and Services Administration, HERSUM, administers 340B through its Office of Pharmacy Affairs. There are six eligibility categories: disproportionate share hospitals, children's hospitals, freestanding cancer hospitals, critical access hospitals, sole community hospitals, rural referral centers. For-profit hospitals are not eligible. Only nonprofit and government-owned facilities qualify. The program has grown dramatically since 1992. By 2010, it was a $6 billion program. By 2020, it was $38 billion. By 2024, it was over $100 billion in covered drug purchases. $340B is on track to become one of the largest government drug programs in the country. Here's how the math works for the hospital. The hospital buys a drug from the manufacturer at the 340B discount. Let's say the discount is 50%. The hospital pays $500 for a drug whose wholesale price is $1,000. The hospital then bills the patient's insurance, Medicare, Medicaid, private insurance, at the full retail price. And sometimes that retail price is $1,500. The hospital has paid $500. The spread is $1,000 per prescription. That spread is the entire economic value of the 340B program for the hospital.

SPEAKER_00 9:46

There are two layers of public information about the 340B program. The distinction between them is the entire story. The first layer is fully transparent. Any listener can go to 340BOPAIS.hersur.gov and search by hospital name, city, or state. You can find out whether your local hospital is a 340 B participant. You can find their enrollment date. You can find their contract pharmacies, the retail pharmacies that dispense their 340 B drugs. You can find their child sites and affiliated locations, and all of it is publicly searchable on a federal website. The second layer is fully opaque. You cannot find out how much the hospital paid for any drug, you cannot find out how much the hospital was reimbursed by Medicare, Medicaid, or private insurance for that drug. You cannot find out the spread the hospital captured. You cannot find out how the hospital used the spread, whether it funded charity care for low-income patients or executive compensation or advertising campaigns or competitive expansion into other markets. You cannot find out which patients received 340B discounted drugs and whether they were the low-income patients the program was designed to serve. All of that is hidden by design.

SPEAKER_01 11:17

In 2024, URSA proposed a pilot program that would have started to close the second layer. The pilot would have required certain hospitals to submit data on how their 340B drugs were actually being dispensed, which patients received them, what the reimbursement spread was, how the proceeds were used. The American Hospital Association sued to block the pilot. So did several other hospital industry groups. A federal

Transparency That Stops At The Money

SPEAKER_01 11:45

court granted an injunction in December 2025. The hospital lobby's argument relied on administrative procedure grounds. But the word they used in public statements to defend the position was patient care. Requiring data submission, they said, would burden hospitals and harm patients. The word patient care was used to prevent the government from finding out whether the program serves patients. That sentence is the entire architecture of this episode.

SPEAKER_00 12:16

In May 2025, President Trump signed an executive order titled Delivering Most Favored Nation Prescription Drug Pricing to American Patients. The premise was that Americans had been paying more for the same drugs than people in Canada, Germany, Japan, and the United Kingdom. The order directed the administration to negotiate prices with pharmaceutical manufacturers that would match the lowest price they charged in any developed country. The word on the executive order was national security. Importing pharmaceuticals at higher prices than other developed nations was framed as a national security issue. That framing gave the president authority to impose tariffs without congressional approval. By April 2026, the administration had reached most favored nation agreements with all 17 major pharmaceutical manufacturers it had targeted. Pfizer signed first in September 2025, nine more in December 2025, ABVA in January 2026, Regeneron in April 2026. In February 2026, the administration launched Trumprx.gov, a direct-to-consumer website where Americans could purchase most favored nation priced drugs. By June 2026, the site offered 750 drugs covering approximately 80% of prescriptions Americans regularly pick up at pharmacies. 12 million unique visitors, $500 million in estimated savings.

SPEAKER_01 13:51

Now here is where the architecture collides. The 340B spread depends on American retail prices being high. The hospital buys at 50% discount and bills at retail. If retail is $1,500, the spread is $1,000 per prescription. That is what funds the program for the hospital. The most favored nation order pushes American retail prices down, toward European levels, toward what Canada pays, toward what Japan pays. As retail prices drop, the spread compresses. Both kinds of 340B hospitals are squeezed simultaneously. The hospital that paid $345 million in kickback settlements and kept its 340B discount the next day, that hospital is being squeezed. But the legitimate rural critical access hospital in a town with 8,000 people, the kind of hospital the 92 legislation was actually designed

Most Favored Nation Meets 340B

SPEAKER_01 14:50

for, where the 340B spread funds the only emergency room within a 50 mile radius. That hospital is also being squeezed, with no mechanism to distinguish between them. The architecture does not know which hospital is which, because the architecture was never required to know.

SPEAKER_00 15:08

There are now four words fighting over the same pile of money. The first word is safety net. The hospital lobby uses it to defend the 340B program. The word is real for some hospitals, critical access hospitals in rural towns, pediatric specialty hospitals, cancer centers in low income communities. For these institutions, the three hundred forty B Spread funds real charity care for real patients. The word is also a shield. The same shield protects the multibillion dollar academic medical center, settling three hundred forty five million dollars in kickback claims. The same shield protects the hospital system spending hundreds of millions on advertising and executive compensation. The word does not distinguish between the rural critical access hospital and the urban academic medical center. The word covers both equally. The second word is national security. The executive branch uses it to justify the most favored nation tariffs and price negotiations. The argument is that Americans should not pay more than Europeans for drugs developed with American research funding. The reasoning is defensible. The word also gives the president authority to act unilaterally on pharmaceutical pricing without Congress, because Congress cannot easily challenge a national security designation. The third word is patient care. The hospital lobby uses it in federal court to block the three hundred forty B transparency pilot. The argument is that requiring data submission burdens hospitals and harms patients. The court granted the injunction the data submission requirement does not exist. The word patient care used to prevent the government from finding out whether the program serves patients. The fourth word is transparency. The federal government uses it to describe Trump RX. The president's administration deploys the word to describe a website where most favored nation priced drugs are visible to consumers. The hospital lobby blocks a different transparency requirement in federal court. Both arguments use the same word. The word does opposite work in each case. Four words, four institutions deploying them, one pile of money. None of the words describes the patient. None of them describes the choice the patient has when she gets to the pharmacy counter and finds out the cost of the prescription her doctor just wrote. None of them looking at the question that actually matters. Just like Moneyball, the people in the room are not even looking at the problem. They are arguing over solutions to a problem the institutions in the room created in the first place. And that misses something fundamental about the American character.

Four Words Fighting Over Cash

SPEAKER_00 18:25

Americans are innovators, tell us we cannot, and we will find a way where we will.

SPEAKER_01 18:32

In 2015, a radiologist named Dr. Alex Oshmiansky sat down and tried to figure out why the generic medications his patients needed had such wildly inconsistent prices. He was a clinician, he was also a mathematician, he had a PhD in applied math from Oxford. He looked at the pharmacy supply chain the way a mathematician looks at any system. He looked for the inefficiency. What he found was that the inefficiency was not a bug in the system. The inefficiency was the system. A generic medication might cost $3 to manufacture. A pharmacy benefit manager, the middleman between the manufacturer and the insurance plan, might add a markup of 1,000% or 5,000%. The patient at the pharmacy counter paid whatever the system decided to charge that day. Sometimes $30 for a 90-day supply. Sometimes $3,000 for the same prescription. There was no obvious reason for the price the patient paid to bear any relationship to the cost of the medication. The price was whatever the network of pharmacy benefit managers, hospitals, manufacturers, and insurance plans had negotiated through a thicket of confidential agreements the patient could never see. Dr. Oshmiyansky started writing a business plan. He was going to build a pharmacy company that did the opposite of what the existing supply chain did. He was going to publish every price. He was going to add a transparent markup. He was going to bypass the pharmacy benefit managers entirely. He needed money. He sent a cold email to a list of billionaires he had compiled. 27 recipients. One of them, a Texas businessman named Mark Cuban, wrote back. Cuban liked the idea. He wrote a check. The company launched in January 2022 as the Mark Cuban Cost Plus Drug Company.

SPEAKER_00 20:28

Here's the formula Cost Plus Drugs uses for every single medication on its site. The price you pay equals the actual cost of the drug plus a 15% markup plus a $3 pharmacy dispensing fee plus $5 for shipping. That is the entire pricing formula published on the website, applied to every drug. If a generic medication costs cost plus drugs $3 to acquire, the price you pay is $3 plus $45 in markup plus the $3 dispensing fee plus $5 for shipping. The retail price for that same medication through traditional pharmacy channels might be $150, or $1,500, or anything in between. The patient pays whatever the system decided. On cost plus drugs, the patient pays $11.45 because the cost is the cost plus 15% plus $3 plus $5.

SPEAKER_01 21:35

The documented results are these. Cost plus drugs now offers over 2,500 medications. The savings versus traditional pharmacy retail are typically between 50 and 95%. A generic version of Imatinobe, the cancer drug Glevec, used to treat chronic myeloid leukemia, sells on Costplus drugs for $14.40 per month.

Cost Plus Drugs Proves Another Way

SPEAKER_01 22:00

The same medication through traditional pharmacy channels can cost up to 9,000 per month. Read that comparison again. The cancer medication that costs $14.40 per month on cost plus drugs has been documented at over $9,000 per month through traditional pharmacy channels. That is not a small markup. That is not a reasonable profit margin. That is the entire architecture this episode has been describing visible in a single drug, in a single comparison, on a single website that anyone can verify by going to costplusdrugs.com right now and searching for the medication. The company is profitable. The company is growing. The company has partnerships with Medicare Advantage plans, with employer health benefit administrators, and with independent pharmacies. The company has not been sued out of existence by the pharmacy benefit managers it bypasses because the company is doing exactly what it says it is doing, with transparent margins on a public website. There is nothing to attack.

SPEAKER_00 23:09

Here is what the cost plus drug company proves, not what it claims, not what it markets, what it documents every day on a public website with every transaction. The architecture is a choice. It is not a necessity. The pharmaceutical pricing system, Americans have been told, is too complicated to understand. The system of rebates and pharmacy benefit managers and three hundred forty B spreads and confidential agreements and inscrutable insurance formularies is not the only possible system. It is the system's specific institutions built to benefit themselves. When someone chose to ignore that system and build a different one, the different one worked. It worked because most of what the existing system charges is not the cost of the medication. It is the cost of the architecture surrounding the medication. The PBMs, the rebate networks, the lobbying, the confidential agreements, the complexity itself, which protects the participants from anyone outside understanding what they are charging. When cost plus drugs strip that complexity out, the prices dropped by 50 to 95%. The patient paid less, the company still made money, the medication still got to the patient. None of the institutions inside the existing architecture were necessary. Now think about what that means for the 340 B story. The hospital that paid $345 million in settlements and kept its three hundred forty B discount the next day, that hospital is inside the architecture. It depends on the architecture. It defends the architecture. Its trade association sues the federal government to keep the architecture opaque. Cost plus drugs is outside the architecture. It does not need 340B. It does not need a federal program designed in 1992. It does not need the spread. It needs only a transparent formula and a customer who can read. And it serves more patients per dollar than the entire 340B program. That is the American spirit. Not the lobbying, not the trade association lawsuit, not the federal hearing, not the consulting firm advising both sides. A radiologist with a math degree wrote a cold email to 27 billionaires. One of them wrote back, they built a pharmacy that publishes its prices. The pharmacy works. That is what an outside the box solution actually looks like. Not a position paper, not a policy framework, not a complicated game designed by institutions that profit from the complexity. A formula on a website plus four hundred employees who run a pharmacy, plus a customer who can read. That is enough. If you have ever stood at a pharmacy counter and watched the price of your prescription change between one month and the next, the same medication, the same dosage, the same insurance card, you have stood inside the architecture this episode describes. If you have ever paid fifty dollars for a generic medication one month and four hundred dollars for the same generic the next month, you have been inside the architecture. If you have ever been told by your pharmacist that your insurance does not cover the medication your doctor prescribed and the cash price is fifteen hundred dollars, you have been inside the architecture. If you have ever rationed a prescription, if you have ever skipped a dose, if you have ever decided that this month the medication is less important than the rent, you have been inside the architecture. If you have used Good RX or Cost Plus Drugs or Amazon Pharmacy or any of the direct to consumer pharmacy services

How Patients Step Outside The System

SPEAKER_00 27:20

that have emerged in the last decade, you have stepped outside the architecture. We want to hear from you. Not just stories of harm, stories of solutions. Times you found a way around the system, times you discovered that the cash price was lower than your insurance copay. Times you bought a ninety day supply of a generic medication for less than your last cup of coffee. Or the harder stories. The medication you needed and could not afford, the decision you made between the prescription and the grocery bill, the pharmacist who quietly told you to ask if there was a cash price. Find us at edge of the story.com. We read everything. The most important stories of the season are coming from listeners. Four episodes into season two, the architecture is now visible at every level. Episode one was the Autism Mandate Medically Necessary $2.2 billion. The wait list for the child. Episode two was the hospice per diem. End of life care. Episode four was the 340 B spread, safety net, national security, patient care, transparency, the four words covering the pile of money. Different industries, different price points, different words. Same architecture. And in every episode, somewhere outside the architecture, the same kind of story keeps appearing. The bakery and corsicana that learned to double check. The Collins Street Ledger, the Wells Fargo teller who said no, the mother who noticed the autism therapist had stopped showing up, and this week the radiologist with the math degree who sent a cold email to twenty-seven billionaires. The architecture is built by institutions, the exits are built by individuals. Next week, episode five, the systems episode. We asked the question the season has been building toward. Who designed the architecture in the first place? Who is paid to maintain it? Who profits when it fails? Who pays for the consulting contracts to fix it? And the question the cabinet official asked at the podium two weeks ago that no one in the room paused on. He said the agency he runs was told to take the guardrails off. He used the word told. Someone gave the instruction. Next week we ask who. Next week on Edge of the Story. The consulting firms

Your Stories And What Comes Next

SPEAKER_00 30:20

that design the rules. Next week we ask who. Edge of the story is produced high atop Chalk Mountain. If the gate is open, stop in and we'll chat a while. If this episode changed how you think about the price you pay at the pharmacy counter, share it. Share it with someone who has been told the system is too complicated to understand. The system is complicated because someone decided it should be. Someone else decided it did not have to be. Every source is in our show notes. The 340B database, the most favored nation executive order, the Trump RX site, the cost plus drugs pricing formula. Every name, every number, every filing. We don't hide our work. We're not investigating the headline. We're investigating how the headline got in the room. See you next week, Episode 5.